COGT on Nasdaq

Cogent Biosciences, Inc.

American pharmaceutical preparations company, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Aclaris Therapeutics, Inc., Pulmatrix, Inc. or Coya Therapeutics, Inc., or pick any stock.

TickerCOGT on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address180 Third Avenue, 4Th Floor, Waltham, Ma²
Filer categoryLarge accelerated filer²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-1044.3%Operating margin³

-950.4%Net margin³

-65.0%Revenue growth, 2020³

-31.9%Return on equity⁴

Where the money goes

Where each dollar of revenue went, fiscal 2020

Research and development

Research and development100¢$25.7M

Out of $7.9M in revenue.³ The company lost money this year.

Financial statements

Revenue⁵³$7.9M in 2020−65% since 2019

Operating income⁵³-$82.2M in 2020+155% since 2019

Net income⁵³-$74.8M in 2020+135% since 2019

Every line of the income statement as filed: the last 3 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Research and development	$269.8M	$232.7M	$173.8M
General and administrative	$63.6M	$43.3M	$34.4M
Total operating expenses	$333.4M	$275.9M	$208.1M
Loss from operations	-$333.4M	-$275.9M	-$208.1M
Interest income	$14.7M	$18.1M	$13.1M
Interest expense	-$3.1M
Loss on debt extinguishment	-$7.2M	$0	$0
Change in fair value of CVR liability	$0	$0	$1.7M
Other income (expense), net	-$20.0K	$2.0M	$943.0K
Total other income, net	$4.4M	$20.1M	$15.7M
Net loss	-$328.9M	-$255.9M	-$192.4M
Net loss per share, basic	-$2.16	-$1.94	-$1.94
Net loss per share, diluted	-$2.16	-$1.94	-$1.94
Weighted average common stock outstanding, basic	128.9M shares	103.9M shares	79.7M shares
Weighted average common stock outstanding, diluted	128.9M shares	103.9M shares	79.7M shares
Net unrealized gains (losses) on marketable securities	-$92.0K	$201.0K	$350.0K
Total other comprehensive income (loss)	-$92.0K	$201.0K	$350.0K
Comprehensive loss	-$329.0M	-$255.7M	-$192.1M

Total assets⁵³$250.9M in 2020+408% since 2019

Total liabilities⁵³$16.2M in 2020−8% since 2019

Shareholders’ equity³⁴$234.7M in 2020+639% since 2019

Cash⁵³$242.2M in 2020+547% since 2019

Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.⁸

Period ending	2025-12-31	2024-12-31	2024-05-31	2024-03-31	2023-12-31
Cash and cash equivalents	$312.0M	$98.2M
Short-term marketable securities	$588.8M	$188.9M
Prepaid expenses and other current assets	$9.6M	$9.4M
Total current assets	$910.4M	$296.5M
Operating lease, right-of-use assets	$18.1M	$20.1M
Property and equipment, net	$5.5M	$6.5M
Restricted cash	$416.0K	$0
Other assets	$3.3M	$4.9M
Total assets	$937.6M	$327.9M
Accounts payable	$9.5M	$12.0M
Accrued expenses and other current liabilities	$52.9M	$42.1M
Operating lease liabilities	$1.5M	$1.6M
Total current liabilities	$64.0M	$55.7M
Convertible senior notes, net	$222.9M	$0
Operating lease liabilities, net of current portion	$14.4M	$15.9M
Other liabilities	$33.0K	$0
Total liabilities	$301.2M	$71.6M
Common stock, $0.001 par value; 300,000,000 shares authorized; 160,980,024 shares and 110,461,729 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	$161.0K	$110.0K
Additional paid-in capital	$1.7B	$1.0B
Accumulated other comprehensive income	$355.0K	$447.0K
Accumulated deficit	-$1.2B	-$859.5M
Total stockholders equity	$636.4M	$256.3M			$257.8M
Total liabilities and stockholders equity	$937.6M	$327.9M
Preferred stock, par value	$0.00
Preferred stock, shares authorized	10.0M shares
Preferred stock, shares issued	0 shares
Preferred stock, shares outstanding	0 shares
Common stock, Par value	$0.00	$0.00
Common stock, Shares authorized	300.0M shares	300.0M shares	300.0M shares	150.0M shares
Common stock, Shares issued	161.0M shares	110.5M shares
Common stock, Shares outstanding	161.0M shares	110.5M shares

Period ending	2025-12-31	2024-12-31	2024-05-31	2024-03-31	2023-12-31	2022-12-31
Cash and cash equivalents	$312.0M	$98.2M
Short-term marketable securities	$588.8M	$188.9M
Prepaid expenses and other current assets	$9.6M	$9.4M
Total current assets	$910.4M	$296.5M
Operating lease, right-of-use assets	$18.1M	$20.1M
Property and equipment, net	$5.5M	$6.5M
Restricted cash	$416.0K	$0
Other assets	$3.3M	$4.9M
Total assets	$937.6M	$327.9M
Accounts payable	$9.5M	$12.0M
Accrued expenses and other current liabilities	$52.9M	$42.1M
Operating lease liabilities	$1.5M	$1.6M
Total current liabilities	$64.0M	$55.7M
Convertible senior notes, net	$222.9M	$0
Operating lease liabilities, net of current portion	$14.4M	$15.9M
Other liabilities	$33.0K	$0
Total liabilities	$301.2M	$71.6M
Common stock, $0.001 par value; 300,000,000 shares authorized; 160,980,024 shares and 110,461,729 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	$161.0K	$110.0K
Additional paid-in capital	$1.7B	$1.0B
Accumulated other comprehensive income	$355.0K	$447.0K
Accumulated deficit	-$1.2B	-$859.5M
Total stockholders equity	$636.4M	$256.3M			$257.8M	$255.7M
Total liabilities and stockholders equity	$937.6M	$327.9M
Preferred stock, par value	$0.00
Preferred stock, shares authorized	10.0M shares
Preferred stock, shares issued	0 shares
Preferred stock, shares outstanding	0 shares
Common stock, Par value	$0.00	$0.00
Common stock, Shares authorized	300.0M shares	300.0M shares	300.0M shares	150.0M shares
Common stock, Shares issued	161.0M shares	110.5M shares
Common stock, Shares outstanding	161.0M shares	110.5M shares

Cash from operations⁵³-$35.9M in 2020−14% since 2019

Every line of the cash flow as filed: the last 3 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Net loss	-$328.9M	-$255.9M	-$192.4M
Depreciation expense	$2.6M	$2.5M	$2.3M
Stock-based compensation expense	$46.1M	$39.7M	$30.6M
Amortization of right-of-use operating lease assets	$2.0M	$1.9M	$1.3M
Change in fair value of CVR liability	$0	$0	-$1.7M
Net amortization (accretion) of premiums (discounts) on marketable securities	-$2.0M	-$7.6M	-$5.2M
Loss on disposal of property and equipment	$0	$0	$8.0K
Amortization of debt discount and issuance costs	$601.0K	$0	$0
Loss on debt extinguishment	-$7.2M	$0	$0
Prepaid expenses and other current assets	-$195.0K	-$4.3M	-$626.0K
Other assets	$1.6M	$2.0K	-$119.0K
Accounts payable	-$2.5M	$1.4M	$4.8M
Accrued expenses and other current liabilities	$10.7M	$16.0M	$8.2M
Operating lease liability	-$1.6M	-$1.4M	-$796.0K
Other liabilities	$33.0K	$0	$0
Net cash used in operating activities	-$264.4M	-$207.8M	-$153.6M
Purchases of property and equipment	-$1.6M	-$573.0K	-$2.8M
Purchases of marketable securities	-$687.2M	-$255.6M	-$348.8M
Maturities and sales of marketable securities	$289.2M	$294.5M	$253.8M
Net cash provided by (used in) investing activities	-$399.5M	$38.3M	-$97.8M
Proceeds from long-term debt	$49.3M	$0	$0
Repayment of long-term debt	-$54.6M	$0	$0
Proceeds from convertible senior notes	$223.1M	$0	$0
Payment of debt issuance costs	-$2.6M	$0	$0
Proceeds from issuance of common stock under ATM, net of issuance costs of $4.9 million	$159.3M	$0	$0
Proceeds from issuance of common stock and Series B non-voting convertible preferred stock in connection with the Private Placement, net of offering costs $11.7 million	$0	$213.3M	$0
Taxes paid related to net share settlement of equity awards	-$48.9M	$0	$0
Proceeds from issuance of common stock upon stock option exercises	$11.5M	$199.0K	$965.0K
Proceeds from issuance of stock from employee stock purchase plan	$1.4M	$916.0K	$752.0K
Net cash provided by financing activities	$878.2M	$214.5M	$163.5M
Net increase (decrease) in cash, cash equivalents and restricted cash	$214.3M	$44.9M	-$87.9M
Cash paid for interest	$2.0M	$0	$0
Debt discount included in accrued expenses and other liabilities	$20.0K	$0	$0
Offering costs included in accounts payable and accrued expenses	$64.0K	$49.0K	$30.0K
Property & equipment included in accounts payable and accrued expenses	$0	$0	$43.0K

Compare Cogent Biosciences, Inc. with another company

Leadership

Who has led Cogent Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Andrews R. Robbins2020–now

President

Chief financial officer

20202025

Chief executive officerAndrews R. Robbins Oct 27, 2020 to now⁹
PresidentAndrews R. Robbins Oct 27, 2020 to now⁹
PresidentChristiana Stamoulis Mar 28, 2018 to Mar 28, 2018¹⁰
Chief financial officerJohn L. Green Jul 8, 2020 to now¹¹
Chief financial officerMatthew Scott Osborne Jun 25, 2019 to Feb 13, 2020¹²

Board members and other officers (17)

Chief Commercial OfficerCole Pinnow May 29, 2024 to now¹³
Chief Scientific OfficerJohn Edward Robinson Apr 15, 2021 to now¹⁴
OfficerJohn L. Green Feb 11, 2019 to Feb 13, 2020¹⁵
Chief Medical OfficerJessica Sachs Jul 17, 2019 to now¹⁶
Chief Medical OfficerMichael Vasconcelles Mar 28, 2018 to Apr 11, 2019¹⁷
Chief Scientific OfficerSeth Ettenberg Mar 28, 2018 to Feb 13, 2020¹⁸
Board memberTodd Shegog Feb 24, 2021 to now¹⁹
Board memberChristopher W. Cain Jul 15, 2020 to now²⁰
Board memberPeter Evan Harwin Jul 15, 2020 to now²¹
Board memberAndrews R. Robbins Oct 27, 2020 to now⁹
Board memberArlene Morris Jul 29, 2019 to now²²
Board memberBruce Booth Mar 28, 2018 to Jul 6, 2020²³
Board memberJorn Aldag Mar 28, 2018 to Jul 6, 2020²⁴
Board memberKaren Jean Ferrante Mar 28, 2018 to now²⁵
Board memberLiam Ratcliffe Mar 28, 2018 to Jun 18, 2019²⁶
Board memberRobert J. Perez Mar 28, 2018 to Jun 18, 2019²⁷
General counselEvan Kearns May 5, 2021 to now²⁸

Former names

Unum Therapeutics Inc.Dec 4, 2017 to Oct 5, 2020²
Unum Therapeutics, Inc.Oct 20, 2014 to Mar 30, 2018²

Timeline

Oct 27, 2020New chief executive Andrews R. Robbins becomes CEO⁹

Filings

314 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 107 insider forms, 81 large holders, 58 other. The latest 20:

Oct 5, 20264 EDGAR
Sep 2, 20268-K EDGAR
Aug 31, 20264 EDGAR
Aug 27, 2026144 EDGAR
Aug 13, 2026SCHEDULE 13G/A EDGAR
Aug 10, 20268-K EDGAR
Aug 10, 2026424B5 EDGAR
Aug 10, 202610-Q EDGAR
Aug 10, 20268-K EDGAR
Jul 31, 2026SCHEDULE 13G EDGAR
Jul 27, 2026SCHEDULE 13G/A EDGAR
Jul 6, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20268-K EDGAR
May 21, 20264 EDGAR

The 314 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 81 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Fmr LLC	25,681,174	$993.9M	0.0%	+2,558,426
BlackRock, Inc.	17,352,646	$671.5M	0.0%	+1,307,632
Vanguard Portfolio Management LLC	8,072,411	$312.4M	0.0%	+739,078
Vanguard Capital Management LLC	7,412,330	$286.9M	0.0%	+517,371
State Street Corp	6,964,919	$269.5M	0.0%	+1,301,376
Jupiter Topco LLC	6,624,848	$256.4M	0.1%	New
Fairmount Funds Management LLC	5,503,418	$213.0M	14.1%	No change
Deerfield Management Company, L.P.	5,006,104	$193.7M	2.4%	−4,037,799
TCG Crossover Management, LLC	4,854,436	$187.9M	4.5%	−92,458
Geode Capital Management, LLC	4,508,998	$174.5M	0.0%	+809,479
Wellington Management Group Llp	4,343,977	$168.1M	0.0%	+765,355
Kynam Capital Management, LP	3,667,097	$141.9M	7.8%	−370,234
Polar Capital Holdings Plc	3,232,905	$125.1M	0.4%	New
Commodore Capital LP	3,050,000	$118.0M	7.0%	+161,993
Assenagon Asset Management S.A.	2,883,512	$111.6M	0.1%	+2,587,862
Invesco Ltd.	2,609,141	$101.0M	0.0%	+179,512
Woodline Partners LP	2,603,162	$100.7M	0.3%	+1,093,605
Pictet Asset Management Holding SA	2,393,515	$92.6M	0.1%	+594,747
Octagon Capital Advisors LP	2,350,000	$90.9M	8.3%	No change
Rtw Investments, LP	2,309,021	$89.4M	0.8%	−3,149,654
Goldman Sachs Group Inc	2,288,633	$88.6M	0.0%	−2,145,421
Candriam S.C.A.	2,088,369	$80.7M	0.4%	+572,072
Deep Track Capital, LP	2,000,000	$77.4M	1.1%	+1,000,000
Siren, L.L.C.	1,859,279	$72.0M	1.5%	+150,000
Orbimed Advisors LLC	1,681,300	$65.1M	1.2%	+1,359,200

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

Date	Member	Trade	Amount	Vs S&P since	Filing
Dec 12, 2022	Christopher L. Jacobs, House	Buy	$1,001 - $15,000	+50.5%	Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARCogent Biosciences, Inc. filings on SEC EDGAR
2
SEC EDGARCogent Biosciences, Inc. filings on SEC EDGAR
3
SEC EDGARCogent Biosciences, Inc. 10-K for fiscal 2020
4
SEC EDGARCogent Biosciences, Inc. 10-K for fiscal 2020
5
SEC EDGARCogent Biosciences, Inc. 10-K for fiscal 2019
6
SEC EDGARCogent Biosciences, Inc. 10-Q for fiscal 2026
7
SEC EDGARCogent Biosciences, Inc. 10-Q for fiscal 2026
8
SEC EDGARCogent Biosciences, Inc. 10-K filed 2026-02-17: income statement
9
SEC EDGARAndrews R. Robbins, Chief executive officer
10
SEC EDGARChristiana Stamoulis, President
11
SEC EDGARJohn L. Green, Chief financial officer
12
SEC EDGARMatthew Scott Osborne, Chief financial officer
13
SEC EDGARCole Pinnow, Chief Commercial Officer
14
SEC EDGARJohn Edward Robinson, Chief Scientific Officer
15
SEC EDGARJohn L. Green, Officer
16
SEC EDGARJessica Sachs, Chief Medical Officer
17
SEC EDGARMichael Vasconcelles, Chief Medical Officer
18
SEC EDGARSeth Ettenberg, Chief Scientific Officer
19
SEC EDGARTodd Shegog, Board member
20
SEC EDGARChristopher W. Cain, Board member
21
SEC EDGARPeter Evan Harwin, Board member
22
SEC EDGARArlene Morris, Board member
23
SEC EDGARBruce Booth, Board member
24
SEC EDGARJorn Aldag, Board member
25
SEC EDGARKaren Jean Ferrante, Board member
26
SEC EDGARLiam Ratcliffe, Board member
27
SEC EDGARRobert J. Perez, Board member
28
SEC EDGAREvan Kearns, General counsel